



Food and Drug Administration Minneapolis District 240 Hennepin Avenue Minneapolis MN 55401-1999 Telephone: 612-334-4100

December 22, 2000

WARNING LETTER

CERTIFIED MAIL RETURN RECEIPT REQUESTED

Refer to MIN 01 - 18

Eugene Monroe, M.D. Chief Executive Officer Advanced Health Care 3003 West Good Hope Road Milwaukee, Wisconsin 53217

Dear Dr. Monroe:

On December 7, 2000, a representative of the State of Wisconsin, acting on behalf of the Food and Drug Administration (FDA), inspected your facility, Milwaukee Medical Clinic, at 3003 West Good Hope Road, Milwaukee, WI (FDA certificate # 1540390). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. Based on the documentation your site presented at the time of the inspection, the following Repeat Level 2 and Level 2 non-compliances were documented at your facility:

Repeat Level 2 Non-Compliance:

1. Three of 10 randomly selected mammography reports reviewed did not contain an approved assessment category at Milwaukee Medical Clinic.

The mammography regulation mandates specific wording for the mammography assessments. FDA, by policy, has approved some additional variants of the official wording. The approved wording was discussed with your site and is available on the Internet site referenced below.

Page Two

Eugene Monroe, M.D. December 22, 2000

This specific problem appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection. It was also cited during the 1999 inspection.

Level 2 Non-Compliances:

- 2. The time period between the previous and current physicist's surveys for X-Ray Unit 2, , OTH exceeds 14 months.
- 3. The time period between the previous and current physicist's surveys for X-Ray Unit 3, WWWWWWOTH exceeds 14 months.

Note: The physicist survey is an <u>annual</u> requirement. The facility is not cited unless the period exceeds 14 months.

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection.

Because these conditions may by symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension of revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within 15 working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures if the findings relate to quality control or other records.

Page Three

Eugene Monroe, M.D. December 22, 2000

Please submit your response to Thomas W. Garvin, Radiological Health Specialist, Food and Drug Administration, 2675 N. Mayfair Road, Suite 200, Milwaukee, WI 53226-1305.

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov/cdrh/mammography/index.html.

If you have specific questions about mammography facility requirements or about the content of this letter, please feel free to phone Mr. Garvin at (414) 771-7167 ext. 12.

Sincerely,

Director

Minneapolis District

TWG/ccl

xc: wwww

Lead Interpreting Radiologist Milwaukee Medical Clinic 3003 West Good Hope Road Milwaukee, WI 53217

Paul Schmidt Chief, Radiation Protection Unit State of Wisconsin P.O. Box 2659 Madison, WI 53701-2659

Priscilla F. Butler Director, Breast Imaging Accreditation Programs American College of Radiology 1891 Preston White Drive Reston, VA 20191